# Xlue

> Research-stage AI predicting future disease risk from patient medical histories.

## Why it is interesting

CMU spinout disclosed $35M Seed led by Conviction on Nov 18 2026. Promising HealthSAW retrospective data, but no proven prospective clinical outcomes.

## Profile

- **Latest funding:** Seed (disclosed; legal close date unverified) — $35M (November 18, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $35M
- **Stage:** seed
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-21
- **Latest funding investors:** Conviction

## Key facts

- CEO Chenyan Xiong; CMU spinout cofounders include Hao-Ren Yao and Ophir Frieder.
- 2025 CATCH-FM 30k cohort, Forbes-reported later 80k cohort and Protege HealthSAW 2.5k test are distinct studies.
- Research partner hospitals and pharma prospects; no proven widespread clinical rollout or published commercial pricing.

## Funding history

- Seed (disclosed; legal close date unverified) · $35M · November 18, 2026
  Source: https://tollbit.forbes.com/sites/innovationrx/2026/11/18/a-carnegie-mellon-researcher-raises-35-million-for-clinical-intelligence

## Investors in our directory

- https://venturecapitaltracker.com/fund/conviction-partners

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 21, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/xlue-health-world-model
